Roche Holding AG (ROG.SW)
Chart Events
Performance Outlook
| Previous Close | 316.90 |
| Open | 320.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 317.30 - 321.10 |
| 52 Week Range | 307.45 - 404.20 |
| Volume | |
| Avg. Volume | 1,553,268 |
| Market Cap | 279.182B |
| Beta (5Y Monthly) | 0.30 |
| PE Ratio (TTM) | 19.74 |
| EPS (TTM) | 16.20 |
| Earnings Date | Jul 21, 2022 |
| Forward Dividend & Yield | 9.30 (2.89%) |
| Ex-Dividend Date | Mar 17, 2022 |
| 1y Target Est | 385.39 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ROG.SW
Related Research
- Zacks
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
- Zacks
Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.
- Reuters
UPDATE 2-Roche believes cancer drug setback not a fatal blow to growth prospects
Roche Holding AG has enough in its drug development pipeline to make up for the recent setback of its keenly-watched experimental cancer drug, Chairman Christoph Franz said on Thursday. On Wednesday, the Swiss drugmaker's stock had its worst day since March 2020, after an interim analysis of an ongoing clinical trial showed its drug, tiragolumab, failed to meaningfully slow disease progression in patients with the most common form of lung cancer. The advantage of a company the size of Roche is that there are several late-stage trials that the company is also banking on to enrich its growth prospects, he suggested.
